Briacell Therapeutics Corp T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

TSX:BCT - Post by User

Briacell Therapeutics Corp

Bullboard Posts

Comment by WatchLearnEarnon Apr 19, 2018 10:01pm

81 Views

Post# 27915065

RE:Release seemed very positive...

You only read the NR with the little bit of polish they could spit-shine it with. Go read the actual posters and then tell us what you think. These results were not "very positive."

tooez1 wrote: Someone did not agree and sold off down to 11.5 cents. Perhaps not specific enough in regard to individual patients? I am disappointed in the stock's response. Expected much better.
Hopefully a delayed positive reaction will occur?

Bullboard Posts

Investors eye Australian gold mining projects amid promising developments